Compare OVID & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVID | DPG |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.5M | 529.2M |
| IPO Year | 2017 | 2011 |
| Metric | OVID | DPG |
|---|---|---|
| Price | $2.78 | $14.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.60 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 44.2K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $1.12 | $12.36 |
| 52 Week High | $3.11 | $15.15 |
| Indicator | OVID | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 36.76 |
| Support Level | $2.38 | $14.06 |
| Resistance Level | $2.77 | $14.81 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 32.26 | 15.54 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.